Literature DB >> 21680779

Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

Bethany L Mundy-Bosse1, Gregory B Lesinski, Alena C Jaime-Ramirez, Kristen Benninger, Mahmood Khan, Periannan Kuppusamy, Kristan Guenterberg, Sri Vidya Kondadasula, Abhik Ray Chaudhury, Krista M La Perle, Melanie Kreiner, Gregory Young, Denis C Guttridge, William E Carson.   

Abstract

Our group and others have determined that immune effector cells from patients with advanced cancers exhibit reduced activation of IFN signaling pathways. We hypothesized that increases in immune regulatory cells termed myeloid-derived suppressor cells (MDSC) could interfere with the host immune response to tumors by inhibiting immune cell responsiveness to IFNs. The C26 murine adenocarcinoma model was employed to study immune function in advanced malignancy. C26-bearing mice had significantly elevated levels of GR1(+)CD11b(+) MDSC as compared with control mice, and splenocytes from tumor-bearing mice exhibited reduced phosphorylation of STAT1 (P-STAT1) on Tyr(701) in response to IFN-α or IFN-γ. This inhibition was seen in splenic CD4(+) and CD8(+) T cells as well as natural killer cells. In vitro coculture experiments revealed that MDSC inhibited the IFN responsiveness of splenocytes from normal mice. Treatment of C26-bearing mice with gemcitabine or an anti-GR1 antibody led to depletion of MDSC and restored splenocyte IFN responsiveness. Spleens from C26-bearing animals displayed elevated levels of iNOS protein and nitric oxide. In vitro treatment of splenocytes with a nitric oxide donor led to a decreased STAT1 IFN response. The elevation in nitric oxide in C26-bearing mice was associated with increased levels of nitration on STAT1. Finally, splenocytes from iNOS knockout mice bearing C26 tumors exhibited a significantly elevated IFN response as compared with control C26 tumor-bearing mice. These data suggest that nitric oxide produced by MDSC can lead to reduced IFN responsiveness in immune cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680779      PMCID: PMC3148319          DOI: 10.1158/0008-5472.CAN-10-2670

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

Authors:  Alessandra Mazzoni; Vincenzo Bronte; Alberto Visintin; Jessica H Spitzer; Elisa Apolloni; Paolo Serafini; Paola Zanovello; David M Segal
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

2.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

Authors:  V Bronte; M Wang; W W Overwijk; D R Surman; F Pericle; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

Review 4.  Interferon-alpha in tumor immunity and immunotherapy.

Authors:  Filippo Belardelli; Maria Ferrantini; Enrico Proietti; John M Kirkwood
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

Review 5.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

6.  IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.

Authors:  Alena Cristina Jaime-Ramirez; Bethany L Mundy-Bosse; SriVidya Kondadasula; Natalie B Jones; Julie M Roda; Aruna Mani; Robin Parihar; Volodymyr Karpa; Tracey L Papenfuss; Krista M LaPerle; Elizabeth Biller; Amy Lehman; Abhik Ray Chaudhury; David Jarjoura; Richard W Burry; William E Carson
Journal:  J Immunol       Date:  2011-02-14       Impact factor: 5.422

7.  Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.

Authors:  Gregory B Lesinski; Sri Vidya Kondadasula; Tim Crespin; Lei Shen; Kari Kendra; Michael Walker; William E Carson
Journal:  J Natl Cancer Inst       Date:  2004-09-01       Impact factor: 13.506

8.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

9.  Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.

Authors:  G Strassmann; C O Jacob; R Evans; D Beall; M Fong
Journal:  J Immunol       Date:  1992-06-01       Impact factor: 5.422

10.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more
  84 in total

Review 1.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 2.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

Review 3.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

4.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

Review 5.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

Review 6.  Immunological off-target effects of standard treatments in gastrointestinal cancers.

Authors:  A G Duffy; T F Greten
Journal:  Ann Oncol       Date:  2013-11-07       Impact factor: 32.976

7.  Expansion of myeloid-derived suppressor cells from peripheral blood decreases after 4-week antiviral treatment in patients with chronic hepatitis C.

Authors:  Ying Liu; Lan-Hui She; Xiang-Yang Wang; Geng-Lin Zhang; Ying Yan; Chao-Shuang Lin; Zhi-Xin Zhao; Zhi-Liang Gao
Journal:  Int J Clin Exp Med       Date:  2014-04-15

8.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

9.  E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.

Authors:  Enguang Bi; Rong Li; Laura C Bover; Haiyan Li; Pan Su; Xingzhe Ma; Chunjian Huang; Qiang Wang; Lintao Liu; Maojie Yang; Zhijuan Lin; Jianfei Qian; Weijun Fu; Yong-Jun Liu; Qing Yi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 10.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.